Pomegranate-Derived Compound Urolithin A Boosts Heart Function by 80% in Experimental Models of Difficult-to-Treat Heart Failure

Researchers at King’s College London have published a breakthrough study in the journal Science Advances revealing that urolithin A—a natural metabolite produced by the human body after the consumption of specific foods such as pomegranates, walnuts, and select berries—can dramatically improve cardiac function. In experimental models of a notoriously difficult-to-treat form of heart failure, the compound enhanced heart relaxation by as much as 80%. Funded by the British Heart Foundation (BHF), the discovery offers a potential new therapeutic avenue for millions of patients worldwide suffering from a condition characterized by a stiffening heart muscle and severely restricted treatment options.

The findings focus on heart failure with preserved ejection fraction (HFpEF), a debilitating condition that accounts for approximately half of all heart failure diagnoses globally. While traditional forms of heart failure involve a heart muscle that has lost its pumping strength, patients with HFpEF retain their heart’s ability to pump blood effectively. However, the heart muscle becomes too rigid to relax properly between beats, preventing the chambers from filling adequately with blood. This mechanical flaw leads to chronic fatigue, severe shortness of breath, a severely diminished capacity for physical exercise, and a steeply declining quality of life.

The Growing Burden of HFpEF and Clinical Challenges

Heart failure with preserved ejection fraction represents one of the most stubborn hurdles in modern cardiovascular medicine. Driven largely by global demographic shifts, the prevalence of HFpEF is surging in tandem with aging populations and rising rates of metabolic disorders such as obesity and type 2 diabetes. High blood pressure, or hypertension, is also a primary catalyst for the disease.

Despite affecting nearly half a million individuals in the UK alone—and millions more internationally—the medical community has struggled to establish effective pharmacological interventions. Because the heart continues to pump with normal force, many conventional heart failure medications designed to boost pumping power are rendered ineffective. Consequently, current clinical management relies almost entirely on treating underlying comorbidities, stabilizing blood pressure, regulating blood sugar, and prescribing rigorous lifestyle modifications, including sustained weight loss and dietary adjustments.

Dr. Joseph Burgoyne, a senior author of the study and a prominent cardiovascular scientist at King’s College London, emphasized the urgency of addressing this medical gap. "This type of heart failure is becoming increasingly common as populations age and rates of obesity and diabetes rise," Dr. Burgoyne stated. "Despite its growing burden, treatment options remain limited because the disease is complex and varies considerably between patients."

Unlocking the Mechanism: How Urolithin A Protects the Heart

The scientific community has spent recent years investigating urolithin A due to its well-documented associations with healthy aging and the optimization of mitochondrial function—the cellular mechanism responsible for generating metabolic energy. However, the King’s College London research team broke new ground by identifying the precise molecular pathway through which urolithin A exerts its cardiovascular benefits.

For the first time, investigators demonstrated that urolithin A activates a vital protein known as PKG1α. This specific protein governs critical physiological processes, including the regulation of blood vessel tone and the relaxation of heart muscle tissue. Urolithin A targets a specific amino acid within the PKG1α protein, triggering a protective biochemical pathway that directly enhances cardiac performance.

In rigorous laboratory evaluations using animal models, administering urolithin A yielded remarkable results. Measures of overall heart function improved by up to 80% when compared to untreated control models. Furthermore, the compound significantly increased the intrinsic ability of heart tissue to relax, while simultaneously curbing fibrosis—the pathological scarring of cardiac tissue that stifles normal contraction and relaxation. The treatment also successfully limited the abnormal enlargement, or hypertrophy, of heart muscle cells, allowing them to preserve normal cellular architecture and function.

Bridging the Gap: Testing on Engineered Human Heart Tissue

To evaluate whether these promising animal and cellular findings could translate to human physiology, the research team advanced their testing to a cutting-edge biomedical model: engineered human heart tissue. Cultured from human stem cells, this sophisticated laboratory construct closely replicates the complex structural and mechanical properties of living human myocardium.

When exposed to urolithin A, the engineered human heart tissue exhibited significant improvements in relaxation capacity. This critical step provides strong preliminary evidence that the cardiovascular benefits observed in preclinical models may successfully translate to human patients.

Crucially, urolithin A holds a distinct translational advantage over many other experimental pharmaceutical compounds. It has already undergone extensive human safety evaluations in separate clinical contexts, demonstrating a highly favorable safety profile and good tolerability.

Expert Perspectives and Official Responses

The implications of the research have drawn praise from major cardiovascular funding bodies, alongside measured cautions regarding translation from the laboratory to the dinner table.

Professor James Leiper, Director of Research at the British Heart Foundation, underscored both the promise of the study and the necessity for rigorous clinical validation. "Heart failure with preserved ejection fraction (HFpEF) makes up roughly half of all heart failure cases in the UK, and can be debilitating," Professor Leiper noted. "This early-stage study in experimental models suggests that urolithin A may help to improve the heart tissue’s ability to relax and fill with blood between beats, reducing the harmful changes to the heart muscle seen in HFpEF."

At the same time, Professor Leiper cautioned against premature dietary self-prescription. "While these findings are promising, the benefits have so far been seen in animals and engineered human tissue, so clinical trials involving people are needed to test if this approach is effective for patients. In the meantime, a healthy, balanced diet remains one of the best ways to look after your heart. Eating plenty of fruit and vegetables is linked to better heart health, but it’s important to remember that no single food can prevent or treat heart disease on its own."

Echoing this sentiment, Dr. Burgoyne clarified that dietary consumption alone cannot currently serve as a standalone medical therapy for established heart disease. "While there isn’t enough evidence to suggest that people should eat pomegranates to treat heart failure, these findings raise the possibility that dietary approaches that enhance urolithin A production may help alleviate this condition," he explained.

Timeline, Next Steps, and Broader Implications

The publication of this study in Science Advances marks a major milestone in a multi-year effort to understand the cellular mechanisms of vascular and cardiac health. Dr. Burgoyne’s broader research laboratory at King’s College London continues to investigate how cells respond to oxidative stress, aiming to uncover foundational biological insights that govern blood pressure, vascular health, and cardiac mechanics.

While the discovery of urolithin A’s action on PKG1α opens an entirely new therapeutic target for drug developers, substantial clinical development remains ahead. The transition from experimental models and engineered tissues to approved human therapies requires comprehensive clinical trials. Researchers must determine optimal dosing strategies, bioavailability, and efficacy in diverse patient populations living with complex comorbidities like diabetes and chronic hypertension.

Should subsequent clinical trials confirm the efficacy of urolithin A in humans, it could pave the way for a revolutionary class of treatments. By harnessing a naturally derived compound that targets the root mechanical failures of HFpEF, medical science moves one step closer to alleviating the burden of a condition that has long resisted conventional cardiovascular therapies, offering renewed hope for enhanced clinical outcomes and a vastly improved quality of life for millions of patients worldwide.